Upgrade to SI Premium - Free Trial

Leerink Partners Continues to View CVS Health (CVS) as a High Quality Stock - Reiterates Outperform

February 9, 2016 2:07 PM
Leerink Partners reiterated an Outperform rating on CVS Health (NYSE: CVS), and cut the price target to $110.00 (from $125.00) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst EPS Change Analyst PT Change

Next Articles